JP2018502168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502168A5 JP2018502168A5 JP2017556787A JP2017556787A JP2018502168A5 JP 2018502168 A5 JP2018502168 A5 JP 2018502168A5 JP 2017556787 A JP2017556787 A JP 2017556787A JP 2017556787 A JP2017556787 A JP 2017556787A JP 2018502168 A5 JP2018502168 A5 JP 2018502168A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- solid oral
- dose
- fingolimod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 claims 11
- 239000006186 oral dosage form Substances 0.000 claims 10
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 5
- 229960000556 fingolimod Drugs 0.000 claims 5
- 239000003826 tablet Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000020937 fasting conditions Nutrition 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105603P | 2015-01-20 | 2015-01-20 | |
| US62/105,603 | 2015-01-20 | ||
| US201562216100P | 2015-09-09 | 2015-09-09 | |
| US62/216,100 | 2015-09-09 | ||
| PCT/US2016/013938 WO2016118515A1 (en) | 2015-01-20 | 2016-01-19 | Stable solid fingolimod dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502168A JP2018502168A (ja) | 2018-01-25 |
| JP2018502168A5 true JP2018502168A5 (enExample) | 2019-02-28 |
Family
ID=56417652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556787A Pending JP2018502168A (ja) | 2015-01-20 | 2016-01-19 | 安定な固体フィンゴリモド剤形 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20230149302A1 (enExample) |
| EP (1) | EP3247341A4 (enExample) |
| JP (1) | JP2018502168A (enExample) |
| CN (1) | CN107530301A (enExample) |
| AU (1) | AU2016209466A1 (enExample) |
| CA (1) | CA2974375A1 (enExample) |
| TW (1) | TW201642842A (enExample) |
| WO (1) | WO2016118515A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020347662A1 (en) * | 2019-09-13 | 2022-03-31 | Meiji Co., Ltd. | Solid food and solid milk |
| JP7503420B2 (ja) * | 2020-05-18 | 2024-06-20 | 東和薬品株式会社 | フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20130200A1 (es) * | 2003-04-08 | 2013-03-09 | Novartis Ag | Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar |
| HUE046441T2 (hu) * | 2006-09-26 | 2020-02-28 | Novartis Ag | S1P modulátort tartalmazó gyógyászati készítmények |
| EP1923055A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator |
| EP1923058A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Coated pharmaceutical composition comprising an S1P agonist or modulator |
| EP3733161A1 (en) * | 2007-10-12 | 2020-11-04 | Novartis AG | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| JP2012508215A (ja) * | 2008-11-11 | 2012-04-05 | ノバルティス アーゲー | 有機化合物 |
| EA201291095A1 (ru) * | 2010-04-22 | 2013-04-30 | Рациофарм Гмбх | Способ получения пероральной лекарственной формы, содержащей финголимод |
| AR085749A1 (es) * | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
| EP2609912A1 (en) * | 2011-12-30 | 2013-07-03 | Deva Holding Anonim Sirketi | Pharmaceutical combination of fingolimod and nabiximols |
| US20140199382A1 (en) * | 2013-01-11 | 2014-07-17 | Cadila Healthcare Limited | Stable pharmaceutical compositions of an s1p receptor agonist |
| US9925138B2 (en) * | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
-
2016
- 2016-01-19 EP EP16740597.6A patent/EP3247341A4/en not_active Withdrawn
- 2016-01-19 CA CA2974375A patent/CA2974375A1/en not_active Abandoned
- 2016-01-19 JP JP2017556787A patent/JP2018502168A/ja active Pending
- 2016-01-19 WO PCT/US2016/013938 patent/WO2016118515A1/en not_active Ceased
- 2016-01-19 AU AU2016209466A patent/AU2016209466A1/en not_active Abandoned
- 2016-01-19 CN CN201680006946.6A patent/CN107530301A/zh active Pending
- 2016-01-20 TW TW105101755A patent/TW201642842A/zh unknown
-
2022
- 2022-12-30 US US18/091,481 patent/US20230149302A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/243,735 patent/US20240050365A1/en not_active Abandoned
-
2024
- 2024-10-18 US US18/919,763 patent/US20250041213A1/en active Pending